Sterling Pharma Solutions Acquires US-Based CiVentiChem

April 5, 2019
Pharmaceutical Technology Editors

Sterling Pharma Solutions has acquired the US arm of complex chemistry solutions provider, CiVentiChem, which is based in Cary, North Carolina, USA.

Contract development and manufacturing organization (CDMO), Sterling Pharma Solutions, has acquired the US arm of complex chemistry solutions provider, CiVentiChem, which is based in Cary, North Carolina, USA.

Through this acquisition, Sterling, a United Kingdom-based company, will be able to offer clients a local US presence while also enhancing its chemistry development capabilities to support pre-clinical and early phase clinical supply. This acquisition has been supported by GHO Capital, a new investor and major stakeholder of Sterling.

“We’re delighted to announce our acquisition of CiVentiChem in the US. We’ve been keen to expand our presence in the US market and the site’s capabilities complement our current service offering,” commented Kevin Cook, CEO of Sterling Pharma Solutions, in a press release. “The North American market now makes up 70% of our customer portfolio, which was one of the major reasons behind the decision to look for a facility in the US. This has been primarily driven by the market’s emerging pharma sector and customer demand for our specialist capabilities in complex and challenging chemistry.”

CiVentiChem will continue to operate out of its own facility in India as a separate entity to Sterling.

Source: Sterling Pharma Solutions